2023年4月17日 · People with localized RCC that’s been surgically removed generally have a very good long-term prognosis. People with higher-risk localized RCC may be offered immunotherapy after the cancer is removed to improve long-term outcomes.

2023年9月28日 · Survival rates for renal cell carcinoma are based on the percentage of people who live at least 5 years after the cancer is discovered. The survival rate differs depending on the cancer stage...

Approximately 20% of patients with renal cell carcinoma (RCC) present with primarily metastatic disease and over 30% of patients with localized RCC will develop distant metastases later, after complete resection of the primary tumor.

The SEER database tracks 5-year relative survival rates for kidney cancer in the United States, based on how far the cancer has spread. The SEER database, however, does not group cancers by AJCC TNM stages (stage 1, stage 2, stage 3, etc.).

2024年2月27日 · Renal cell carcinoma (RCC) is a common malignancy of the urinary tract. In the United States, 81,000 new cases of RCC were diagnosed in 2023, and there were 14,890 related deaths 1. RCC’s...

TFE3 re-arranged RCC (formerly called RCC with Xp11.2 translocation) has a poor prognosis [204]. Its incidence is low, but its presence should be systematically assessed in young patients. Renal cell carcinoma type classification has been confirmed by cytogenetic and genetic analyses [205-207] (LE: 2b).

2024年3月28日 · According to the ACS, the 5-year survival rate for people with stage 4 kidney cancer is 17%. This reflects the number of people who are still alive after 5 years of their RCC stage 4 diagnosis.

Several factors and models predict prognosis of localised and metastatic RCC. They represent valuable tools to provide estimates of clinically important endpoints, but their accuracy should be improved further. Validation of molecular markers is a future research priority.

There is increasing knowledge on prognostic factors of localized and metastatic RCC. Several predictive models have been developed by combining different prognostic features and are valuable tools for patient counseling, treatment decision-making and trial design.

Prognosis for Renal Cancer Five-year survival rates range from over 90% for localized disease to less than 20% for those with distant metastases ( 1 ). Prognosis is poor for patients with metastatic or recurrent renal cell carcinoma (RCC) because treatments are usually ineffective for cure, although they may be useful for palliation.